Emerging therapies for the treatment of psoriasisCitation formats

Standard

Emerging therapies for the treatment of psoriasis. / Patel, Mahir; Day, Antoinette; Warren, Richard B.; Menter, Alan.

In: Dermatology and Therapy, Vol. 2, No. 1, 2012, p. 1-10.

Research output: Contribution to journalArticlepeer-review

Harvard

Patel, M, Day, A, Warren, RB & Menter, A 2012, 'Emerging therapies for the treatment of psoriasis', Dermatology and Therapy, vol. 2, no. 1, pp. 1-10. https://doi.org/10.1007/s13555-012-0016-4

APA

Patel, M., Day, A., Warren, R. B., & Menter, A. (2012). Emerging therapies for the treatment of psoriasis. Dermatology and Therapy, 2(1), 1-10. https://doi.org/10.1007/s13555-012-0016-4

Vancouver

Patel M, Day A, Warren RB, Menter A. Emerging therapies for the treatment of psoriasis. Dermatology and Therapy. 2012;2(1):1-10. https://doi.org/10.1007/s13555-012-0016-4

Author

Patel, Mahir ; Day, Antoinette ; Warren, Richard B. ; Menter, Alan. / Emerging therapies for the treatment of psoriasis. In: Dermatology and Therapy. 2012 ; Vol. 2, No. 1. pp. 1-10.

Bibtex

@article{639dfa91c2264ac48920021eccf12572,
title = "Emerging therapies for the treatment of psoriasis",
abstract = "Psoriasis is an immune-mediated disease that affects 1%-2% of the European and North American population. While topical agents such as corticosteroids and vitamin D derivatives are prescribed for mild disease, they are generally unable to adequately control patients with more severe disease. Over the past decade, research into the immunopathogenesis of psoriasis, including investigations into the role of tumor necrosis factor-alpha and more recently interleukins (IL) 12/23, has led to the advent of targeted biologic therapies based on the central role of a new subset of T cells, Th17. Because of their increased specificity, biologic agents have revolutionized short- to medium-term treatment outcomes and safety profiles for moderate to severe disease over previously gold standard systemic agents. The immunopathogenesis of the disease is still a focus for researchers and novel targets for future agents are being discovered and investigated in clinical trials. In particular, specifically targeting the IL-23/Th17 pathway has given rise to IL- 23p19 and IL-17 antagonists, both of which have shown significant promise in clinical trials. IL-22 is involved in keratinocyte proliferation and is being studied as a treatment target for psoriasis. New small molecule oral agents, including Janus kinase and phosphodiesterase inhibitors are currently in phase 2 and 3 clinical trials. {\textcopyright} The Author(s) 2012.",
keywords = "Biologic therapies, Interleukin-12/23, Interleukin-17, Interleukin-20/22, Janus kinase inhibitors, Phosphodiesterase 4 inhibitors, Psoria",
author = "Mahir Patel and Antoinette Day and Warren, {Richard B.} and Alan Menter",
year = "2012",
doi = "10.1007/s13555-012-0016-4",
language = "English",
volume = "2",
pages = "1--10",
journal = "Dermatology and Therapy",
issn = "2193-8210",
publisher = "Springer Nature",
number = "1",

}

RIS

TY - JOUR

T1 - Emerging therapies for the treatment of psoriasis

AU - Patel, Mahir

AU - Day, Antoinette

AU - Warren, Richard B.

AU - Menter, Alan

PY - 2012

Y1 - 2012

N2 - Psoriasis is an immune-mediated disease that affects 1%-2% of the European and North American population. While topical agents such as corticosteroids and vitamin D derivatives are prescribed for mild disease, they are generally unable to adequately control patients with more severe disease. Over the past decade, research into the immunopathogenesis of psoriasis, including investigations into the role of tumor necrosis factor-alpha and more recently interleukins (IL) 12/23, has led to the advent of targeted biologic therapies based on the central role of a new subset of T cells, Th17. Because of their increased specificity, biologic agents have revolutionized short- to medium-term treatment outcomes and safety profiles for moderate to severe disease over previously gold standard systemic agents. The immunopathogenesis of the disease is still a focus for researchers and novel targets for future agents are being discovered and investigated in clinical trials. In particular, specifically targeting the IL-23/Th17 pathway has given rise to IL- 23p19 and IL-17 antagonists, both of which have shown significant promise in clinical trials. IL-22 is involved in keratinocyte proliferation and is being studied as a treatment target for psoriasis. New small molecule oral agents, including Janus kinase and phosphodiesterase inhibitors are currently in phase 2 and 3 clinical trials. © The Author(s) 2012.

AB - Psoriasis is an immune-mediated disease that affects 1%-2% of the European and North American population. While topical agents such as corticosteroids and vitamin D derivatives are prescribed for mild disease, they are generally unable to adequately control patients with more severe disease. Over the past decade, research into the immunopathogenesis of psoriasis, including investigations into the role of tumor necrosis factor-alpha and more recently interleukins (IL) 12/23, has led to the advent of targeted biologic therapies based on the central role of a new subset of T cells, Th17. Because of their increased specificity, biologic agents have revolutionized short- to medium-term treatment outcomes and safety profiles for moderate to severe disease over previously gold standard systemic agents. The immunopathogenesis of the disease is still a focus for researchers and novel targets for future agents are being discovered and investigated in clinical trials. In particular, specifically targeting the IL-23/Th17 pathway has given rise to IL- 23p19 and IL-17 antagonists, both of which have shown significant promise in clinical trials. IL-22 is involved in keratinocyte proliferation and is being studied as a treatment target for psoriasis. New small molecule oral agents, including Janus kinase and phosphodiesterase inhibitors are currently in phase 2 and 3 clinical trials. © The Author(s) 2012.

KW - Biologic therapies

KW - Interleukin-12/23

KW - Interleukin-17

KW - Interleukin-20/22

KW - Janus kinase inhibitors

KW - Phosphodiesterase 4 inhibitors

KW - Psoria

U2 - 10.1007/s13555-012-0016-4

DO - 10.1007/s13555-012-0016-4

M3 - Article

C2 - 23205338

VL - 2

SP - 1

EP - 10

JO - Dermatology and Therapy

JF - Dermatology and Therapy

SN - 2193-8210

IS - 1

ER -